IPO
Recent changes
- Aug 9, 2026Aug 9, 2026BillionToOne's Selloff Is a Warning for Biotech IPOs Pulse story
Latest Pulse
- Sep 22, 2026This Fall's Biotech IPOs Are Splitting Into Pops And DropsRecent biotech IPO debuts have split sharply: Parabilis Medicines popped 66.75% and BillionToOne jumped 66.67% on debut, while Electra Therapeutics closed down nearly 12% this week -- a mixed signal inside one reopened window.→
- Sep 21, 2026Electra Therapeutics Closes First Day Down 12%Electra Therapeutics priced its upsized IPO at $15 a share for roughly $350 million, then closed its first trading day on Nasdaq down nearly 12% at $13.25 -- a rockier debut than the biotech IPO market's recent run of first-day pops.→
- Aug 9, 2026Caris Leads a Wild Week for Recent IPO StocksCaris Life Sciences jumped 21.6% on a beat-and-raise quarter while BillionToOne fell 29.8% despite beating estimates, the sharpest split in the Renaissance IPO Index in weeks.→
- Aug 9, 2026BillionToOne's Selloff Is a Warning for Biotech IPOsBillionToOne beat Q2 estimates by a wide margin and still fell nearly 30% because it reiterated rather than raised guidance -- a signal about how little room newly public companies have left to disappoint.→
Coverage Timeline
newest firstAll Coverage
IPO
This Fall's Biotech IPOs Are Splitting Into Pops And Drops
Recent biotech IPO debuts have split sharply: Parabilis Medicines popped 66.75% and BillionToOne jumped 66.67% on debut, while Electra Therapeutics closed down nearly 12% this week -- a mixed signal inside one reopened window.
BY THE NUMBERS
IPO
Caris Leads a Wild Week for Recent IPO Stocks
IPO
Caris Leads a Wild Week for Recent IPO Stocks
Caris Life Sciences jumped 21.6% on a beat-and-raise quarter while BillionToOne fell 29.8% despite beating estimates, the sharpest split in the Renaissance IPO Index in weeks.
BRIEF
IPO
BillionToOne's Selloff Is a Warning for Biotech IPOs
IPO
BillionToOne's Selloff Is a Warning for Biotech IPOs
BillionToOne beat Q2 estimates by a wide margin and still fell nearly 30% because it reiterated rather than raised guidance -- a signal about how little room newly public companies have left to disappoint.
TRACE'S TAKE